Hypertrophic responses to cardiotrophin-1 are not mediated by STAT3, but via a MEK5-ERK5 pathway in cultured cardiomyocytes

Journal of Molecular and Cellular Cardiology

Volumn 38, Issue 1, 2005, Pages 185-192

  Takahashi, Nobuki ^a   Saito, Yoshihiko ^b   Kuwahara, Koichiro ^a   Harada, Masaki ^a   Tanimoto, Keiji ^a   Nakagawa, Yasuaki ^a   Kawakami, Rika ^a   Nakanishi, Michio ^a   Yasuno, Shinji ^a   Usami, Satoru ^a   Yoshimura, Akihiko ^c   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Cardiomyocyte; Cardiotrophin 1; Cell signaling; Cytokine; ERK1 2; ERK5; Hypertrophy; STAT3

Indexed keywords

CARDIOTROPHIN 1; CYTOKINE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; HEART MUSCLE CELL; HYPERTROPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; CELLS, CULTURED; CYTOKINES; DNA-BINDING PROTEINS; FLAVONOIDS; MAP KINASE KINASE 1; MAP KINASE KINASE 5; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 7; MYOCYTES, CARDIAC; PHOSPHORYLATION; RATS; RATS, WISTAR; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

JANUS;

EID: 19944380417     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2004.10.016     Document Type: Article

References (33)

1. K.C. Wollert, and K.R. Chien Cardiotrophin-1 and the role of gp130-dependent signaling pathways in cardiac growth and development J. Mol. Med. 75 1997 492 501
2. H. Hirota, K. Yoshida, T. Kishimoto, and T. Taga Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice Proc. Natl. Acad. Sci. USA 92 1995 4862 4868
3. H. Hirota, J. Chen, U.A. Betz, K. Rajewsky, Y. Gu, and J. Ross Jr. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress Cell 97 1999 189 198
4. K. Kuwahara, Y. Saito, I. Kishimoto, Y. Miyamoto, M. Harada, and E. Ogawa Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes J. Mol. Cell. Cardiol. 32 2000 1385 1394
5. K. Kunisada, E. Tone, Y. Fujio, H. Matsui, K. Yamauchi-Takihara, and T. Kishimoto Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes Circulation 98 1998 346 352
6. K. Kunisada, S. Negoro, E. Tone, M. Funamoto, T. Osugi, and S. Yamada Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy Proc. Natl. Acad. Sci. USA 97 2000 315 319
7. R. Starr, T.A. Willson, E.M. Viney, L.J. Murray, J.R. Rayner, and B.J. Jenkins A family of cytokine-inducible inhibitors of signalling Nature 387 1997 917 921
8. T.A. Endo, M. Masuhara, M. Yokouchi, R. Suzuki, H. Sakamoto, and K. Mitsui A new protein containing a SH2 domain that inhibits JAK kinases Nature 387 1997 921 924
9. T. Naka, M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, and A. Aono Structure and function of a new STAT-induced STAT inhibitor Nature 387 1997 924 929
10. I. Hamanaka, Y. Saito, H. Yasukawa, I. Kishimoto, K. Kuwahara, and Y. Miyamoto Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo Circ. Res. 88 2001 727 732
11. H. Kodama, K. Fukuda, J. Pan, M. Sano, T. Takahashi, and T. Kato Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy Am. J. Physiol. Heart Circ. Physiol. 279 2000 H1635 H1644
12. R.L. Nicol, N. Frey, G. Pearson, M. Cobb, J. Richardson, and E.N. Olson Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy EMBO J. 20 2001 2757 2767
13. M. Minami, M. Inoue, S. Wei, K. Takeda, M. Matsumoto, and T. Kishimoto STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line Proc. Natl. Acad. Sci. USA 93 1996 3963 3966
14. H. Yasukawa, M. Hoshijima, Y. Gu, T. Nakamura, S. Pradervand, and T. Hanada Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways J Clin Invest 108 2001 1459 1467
15. J.M. English, G. Pearson, T. Hockenberry, L. Shivakumar, M.A. White, and M.H. Cobb Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control J. Biol. Chem. 274 1999 31588 31592
16. T. Ueyama, S. Kawashima, T. Sakoda, Y. Rikitake, T. Ishida, and M. Kawai Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy J. Mol. Cell. Cardiol. 32 2000 947 960
17. Y. Kanegae, G. Lee, Y. Sato, M. Tanaka, M. Nakai, and T. Sakaki Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase Nucleic Acids Res. 23 1995 3816 3821
18. M. Harada, H. Itoh, O. Nakagawa, Y. Ogawa, Y. Miyamoto, and K. Kuwahara Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes Circulation 96 1997 3737 3744
19. K. Nakao, Y. Ogawa, S. Suga, and H. Imura Molecular biology and biochemistry of the natriuretic peptide system. I: natriuretic peptides J. Hypertens. 10 1992 907 9012
20. K. Kuwahara, Y. Saito, M. Harada, M. Ishikawa, E. Ogawa, and Y. Miyamoto Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro Circulation 100 1999 1116 1124
21. K.C. Wollert, T. Taga, M. Saito, M. Narazaki, T. Kishimoto, and C.C. Glembotski Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways J. Biol. Chem. 271 1996 9535 9545
22. D.R. Alessi, A. Cuenda, P. Cohen, D.T. Dudley, and A.R. Saltiel PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo J. Biol. Chem. 270 1995 27489 27494
23. S. Kamakura, T. Moriguchi, and E. Nishida Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus J. Biol. Chem. 274 1999 26563 26571
24. J.E. Railson, Z. Liao, B.K. Brar, J.C. Buddle, D. Pennica, and A. Stephanou Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes Cytokine 17 2002 243 253
25. H. Kodama, K. Fukuda, J. Pan, S. Makino, A. Baba, and S. Hori Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes Circ. Res. 81 1997 656 663
26. H. Oh, Y. Fujio, K. Kunisada, H. Hirota, H. Matsui, and T. Kishimoto Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes J. Biol. Chem. 273 1998 9703 9710
27. N. Mody, J. Leitch, C. Armstrong, J. Dixon, and P. Cohen Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway FEBS Lett 502 2001 21 24
28. K. Yoshida, T. Taga, M. Saito, S. Suematsu, A. Kumanogoh, and T. Tanaka Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders Proc. Natl. Acad. Sci. USA 93 1996 407 411
29. C.P. Regan, W. Li, D.M. Boucher, S. Spatz, M.S. Su, and K. Kuida Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects Proc. Natl. Acad. Sci. USA 99 2002 9248 9253
30. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N. Engl. J. Med. 316 1987 1429 1435
31. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N. Engl. J. Med. 325 1991 293 302
32. K. Swedberg, P. Held, J. Kjekshus, K. Rasmussen, L. Ryden, and H. Wedel Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N. Engl. J. Med. 327 1992 678 684
33. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N. Engl. J. Med. 327 1992 685 691